Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccine D46/NS2/N/ΔM2-2-HindIII in Infants
NCT03102034Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of D46/NS2/N/ΔM2-2-HindIII in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Solicited Adverse Events, Number of Participants With Unsolicited Adverse Events and 6 more. Started Apr 2017; status: completed.
02
Drugs
D46/NS2/N/ΔM2-2-HindIII
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03102034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102034.